Press Release

HOOKIPA Pharma Presents Additional
Preliminary Phase 2 Data on HB-200 in
Combination with Pembrolizumab as
First-Line Treatment in Patients with
HPV16+ Head and Neck Cancers at
ESMO 2023

Learn More